Promising results have been reported in patients with Metastatic castrationresistant prostate cancer (mCRPC) treated with Prostate-specific membrane antigen (PSMA) Radio-ligand therapy (RLT) [2, 3]. The gene discussed is FOLH1; the disease is prostate carcinoma.